Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2410951 | Vaccine | 2005 | 8 Pages |
Abstract
Recent prophylactic vaccine trials inducing virus-specific CD8+ T-cell responses have shown control of primary infections of a pathogenic simian-human immunodeficiency virus (SHIV) in macaques. In the chronic phase, therapeutic immunization replenishing virus-specific CD8+ T-cells is likely to contribute to sustained control of virus replication. In this study, we have administered a recombinant Sendai virus (SeV) vector into five rhesus macaques that had received prophylactic vaccinations and had controlled SHIV replication for more than 1 year after challenge. Our results indicate that virus-specific CD8+ T-cell responses can be expanded and broadened by therapeutic immunization with SeV vectors in the chronic phase after prophylactic vaccine-based control of primary immunodeficiency virus infections.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Moriaki Kato, Hiroko Igarashi, Akiko Takeda, Yuri Sasaki, Hiromi Nakamura, Munehide Kano, Tetsutaro Sata, Akihiro Iida, Mamoru Hasegawa, Shigeo Horie, Eiji Higashihara, Yoshiyuki Nagai, Tetsuro Matano,